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 Abbreviations 
 
ΑΕ Adverse event 
ALT alanine aminotransferase 
AST aspartate aminotransferase 
CEC Clinical Endpoint Committee 
CHA2DS2-VASc score a score that calculates the stroke risk for patients 
with atrial  fibrillation 
CLCR creatinine clearance 
CNS central nervous system 
CRF case report form 
DMC Data Monitoring Committee 
DVT deep vein thrombosis 
GCP Good Clinical Practice 
ICH International Conference on Harmonisation 
INR International Normalized Ratio 
ITT intention-to-treat 
IVRS interactive voice response system 
LFT liver function test 
LMWH low molecular weight heparin 
PE pulmonary embolism 
POC Point of care 
SAE Serious adverse event 
SEE Systemic Embolic Events 
SGOT aspartate aminotransferase 
SGPT alanine aminotransferase 
TIA transient ischemic attack 
ULN upper limit of normal 
VKA vitamin K antagonist 
VTE venous thromboembolism 
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SYNOPSIS 
 
 
Title of study 
 
A Phase 3, Active (Warfarin) controlled, 
double-blind, double-dummy, randomized 
Study for assessing the efficacy and safety of 
rivaroxaban in patients with non-valvular 
Atrial Fibrillation. 
 
Investigational Product 
 
 
Rivaroxaban 
 
Active Ingredient 
 
5-Chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-
morpholinyl)phenyl]-1,3-oxazolidin-5-
yl}methyl)-2-thiophenecarboxamide 
 
Study Phase 
 
 
3 
 
Research Hypothesis 
 
Rivaroxaban is non-inferior to dose-adjusted 
warfarin for the prevention of the composite 
endpoint of stroke and non-CNS systemic 
embolism in subjects with non-valvular atrial 
fibrillation 
 
 
 
Primary Efficacy Objective 
 
To determine if rivaroxaban is noninferior to 
warfarin (INR target range 2.0 - 3.0) in the 
combined endpoint of stroke (ischemic or 
hemorrhagic or unspecified type) and 
systemic embolism, in subjects with non-
valvular AF who were at moderate-to-high 
risk for stroke 
 
 
 
Primary Safety Objective 
 
To demonstrate that rivaroxaban is superior 
to dose-adjusted warfarin as assessed by the 
composite of major and non-major clinically 
relevant bleeding events. 
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Secondary Objectives 
• To compare rivaroxaban to warfarin 
with regard to the composite clinical outcome 
of stroke, non-CNS systemic embolism, and 
vascular death as well as each component 
separately. 
• To compare rivaroxaban to warfarin 
with regard to the composite of MI, non-fatal 
stroke, non-fatal SEE, and death due to 
cardiovascular cause or bleeding. 
• To compare the effects of 
rivaroxaban and warfarin with respect to 
disabling stroke (severity of strokes 
according to modified Rankin scale) and all-
cause mortality 
• To evaluate the safety of rivaroxaban 
vs. warfarin with respect to:  
 Individual bleeding 
event categories,  
 All other clinical and 
laboratory safety 
assessments 
including liver 
enzyme and bilirubin 
abnormalities. 
 
 
 
 
 
 
 
Study design 
 
This is an event-driven, Phase 3, multi-
center, randomized, double-blind, double-
dummy, parallel-group study. The study will 
be divided into a screening period, a double-
blind treatment period and a post-treatment 
observation period. 
To maintain the study blinding a double-
dummy technique will be used. So with the 
use of an interactive voice response system, 
subjects will be randomly assigned in a 1:1 
ratio to one of the following two groups: 
 subjects randomly assigned to 
rivaroxaban, will receive rivaroxaban 
20 mg (or 15 mg for subjects with 
moderate renal impairment) plus 
warfarin placebo p.o. and 
 subjects randomly assigned to 
warfarin will receive warfarin titrated 
to a target INR of 2,5  plus 
rivaroxaban placebo p.o. 
Warfarin and its matching placebo will be 
dose-adjusted based on either real or sham 
INR results, respectively, which will be 
provided by a specially designed point-of-
care INR device, so that the study blinding is 
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protected. 
 
Study Duration 
 
 
This is an event-driven study. The study will 
continue until 445 primary endpoint events 
occur in the per protocol population. 
 
 
 
 
 
 
Study Population 
 
The study population consists of adults with 
documented non-valvular atrial fibrillation 
and a history of stroke, transient ischemic 
attack, or systemic embolism or at least two 
of the following risk factors: heart failure or a 
left ventricular ejection fraction of 35% or 
less, hypertension, an age of 75 years or 
more, or the presence of diabetes mellitus. 
Potential subjects who meet any of the 
following criteria will be excluded from 
participating in the study: hemodynamically 
significant mitral stenosis, prosthetic heart 
valve, planned cardioversion, increased 
bleeding risk (e.g. history of intracranial 
hemorrhage, known intracranial neoplasm or 
aneurysm or clinically significant 
gastrointestinal bleeding ),planned major 
surgery, simultaneous treatment with both 
aspirin and a thienopyridine, severe renal 
insufficiency (calculated creatinine  clearance 
< 30 mL/min), known significant liver 
disease, pregnancy or breast-feeding. 
 
 
 
 
 
 
 
 
 
 
Statistical Methods 
 
This is an event-driven trial that aims to 
establish that rivaroxaban is non-inferior to 
warfarin by a non-inferiority margin of 1.38 
in terms of risk (hazard) ratio. This means 
that we need approximately 445 adjudicated 
primary efficacy events and about 14.834 
patients (for a power of 90% and a 
confidence interval of 95%).An interim 
analysis will take place when either 50% of 
the primary efficacy events have occurred or 
at a maximum of 18 months after the first 
subject is randomized. 
The Cox proportional hazards Model with 
treatment as a covariate and a 2-sided 95% 
confidence interval for the hazard ratio 
rivaroxaban/warfarin will be used for the 
assessment of the primary efficacy endpoint 
in both the per protocol and in the intention-
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to-treat population, while on treatment. 
If non-inferiority for the primary efficacy 
endpoint is satisfied, then non-inferiority for 
the secondary efficacy endpoints on the per 
protocol population will be tested, using the 
same approach described above. 
If non-inferiority for each secondary efficacy 
endpoint on the per-protocol population is 
satisfied, then superiority for the respective 
secondary efficacy endpoint on the ITT 
population while on treatment will be tested. 
 
The principal safety endpoint is the 
composite of major and non-major clinically 
relevant bleeding events. Time from 
randomization to the first occurrence of a 
principal safety endpoint event will be 
analyzed based on the safety population 
while on treatment using the Cox 
Proportional Hazards model with treatment 
as a covariate. 
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1 INTRODUCTION 
 
1.1 Backround 
Atrial fibrillation is the most common cardiac arrhythmia of clinical significance and its prevalence 
increases with age, being less than 1% among people under 60 years of age with estimates of more 
than 6% among those over 80 years of age. It predisposes to the development of atrial thrombi, most 
commonly in the left atrial appendage, and for this reason atrial fibrillation is associated with an 
increase in the risk of ischemic stroke by a factor of four to five and it accounts for up to 15% of 
strokes in persons of all ages and 30% in persons over the age of 80 years. Vitamin K antagonists, 
such as warfarin, reduce the risks of stroke and death but increase the risk of hemorrhage as compared 
with control therapy. Therefore, warfarin is recommended for patients who have atrial fibrillation and 
are at risk for stroke. 
Despite the established efficacy of vitamin K antagonists, they are cumbersome to use, because of 
their multiple interactions with food and drugs, and they require frequent laboratory monitoring. 
Therefore, they are often not used, and when they are, rates of discontinuation are high. Many patients 
receiving warfarin still have inadequate anticoagulation. Thus, there is a need for new anticoagulant 
agents that are effective, safe, and convenient to use. 
Rivaroxaban is a highly selective oral direct factor Xa inhibitor that may provide more consistent and 
predictable anticoagulation than warfarin. It has been reported to prevent venous thromboembolism 
more effectively than enoxaparin in patients undergoing orthopedic surgery and was noninferior to 
enoxaparin followed by warfarin in a study involving patients with established venous thrombosis. 
This trial is designed to compare once-daily oral rivaroxaban with dose-adjusted warfarin for the 
prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, who are at 
moderate-to-high risk for stroke. 
1.2 Rivaroxaban 
 
Activation of factor X plays a central role in the cascade of blood coagulation. Selective inhibition of 
FXa should inhibit thrombin generation and result in a potent antithrombotic effect. The inhibition of 
FXa for the treatment and prevention of thrombotic conditions is a well-validated approach. This 
mechanism has been successfully demonstrated by the low molecular weight heparins (LMWHs), 
enoxaparin in particular. Indeed, this therapy is currently indicated for the prevention of VTEs 
associated with orthopedic surgery and in high-risk patients during hospitalization , for the treatment 
of deep vein thrombosis (DVT) with or without pulmonary embolism (PE) and for the prophylaxis of 
ischemic events in patients presenting with acute coronary syndromes. 
 
1.2.1   Nonclinical Studies  
In summary, preclinical pharmacology studies of rivaroxaban showed:  
• Competitive, selective, direct inhibition of human FXa  
• Inhibition of prothrombinase, with resultant anticoagulant activity, but no significant interaction 
with platelet function  
• Species-dependent inhibition of FXa, with resultant antithrombotic activity in venous and 
arterial thrombosis models in rats and rabbits  
• Excellent correlation between clotting times (e.g., PT) and plasma levels  
• Antithrombotic activity without excessive prolongation of bleeding time in rats and rabbits  
•Bleeding risk comparable with enoxaparin  
• Co-administration of rivaroxaban with acetylsalicylic acid, naproxen, diclofenac, clopidogrel, or 
warfarin showed additive but not potentiating effects on bleeding time prolongation in the tail 
transection model in rats.  
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1.2.2 Clinical Studies 
As of December 2005 a total of 33 Phase 1 studies involving 878 subjects have been conducted, with 
735 subjects exposed to at least 1 dose of rivaroxaban and 143 to placebo. As of February 2006 a total 
of 2,232 subjects were exposed to rivaroxaban and 555 to the comparator enoxaparin in 4 completed 
Phase 2 studies for VTE prophylaxis after orthopedic surgery. In 1 completed Phase 2 study of DVT 
treatment, 883 subjects have been exposed to rivaroxaban and 263 to comparator drugs. 
 
Phase 1 Studies  
In the Phase 1 clinical pharmacology studies, rivaroxaban was well tolerated with no relevant safety 
parameters being affected in male volunteers, 18 to 45 years of age, at single doses up to 80 mg and 
multiple doses up to 30mg twice daily. In elderly subjects, no relevant safety parameters were affected 
after single dose administrations of 30 mg, 40 mg, and 50 mg rivaroxaban. Rivaroxaban does not 
influence bleeding time to a clinically relevant extent. Prolongation of PT is very closely correlated 
with plasma concentrations. Thrombin generation is inhibited dose dependently with all parameters 
being influenced (lag time, peak and total effect). Both pathways of coagulation (intrinsic and 
extrinsic) are affected. 
 
Rivaroxaban pharmacokinetics are linear, with no relevant undue accumulation beyond steady state, 
which is achieved after 2 to 3 days. 
  
Food increases the absorption of rivaroxaban by 30% for the area under the concentration versus time 
curve (AUC), independent of the food content, and decreases variability, whereas changes of gastric 
pH (ranitidine) or chelating drugs (Maalox) have no influence on pharmacokinetics and 
pharmacodynamics. 
 
Inhibition of cytochrome 3A4 by ketoconazole results in an increase in plasma concentrations by 
about 2.6-fold for AUC. 
 
Because approximately one-third of the administered rivaroxaban dose is excreted renally as 
unchanged drug, renal insufficiency is expected to affect drug elimination. Data from a phase I study 
showed an increase in rivaroxaban exposure correlated to decreased renal function, as assessed via 
creatinine clearance (CLCR) measurements. In subjects with mild (CLCR 50–80 mL/min), moderate 
(CLCR 30–49 mL/min), and severe (CLCR 15–29 mL/min) renal impairment, rivaroxaban plasma 
concentrations (AUC) were increased 1.4-, 1.5-, and 1.6-fold, respectively, compared with subjects 
with normal renal function. The increase in AUC was inversely correlated with the CLCR rate, and 
there was a close correlation between the renal and total body clearance of rivaroxaban and the CLCR 
rates of the subjects. Renal clearance decreased from 2.4 L/h in healthy subjects to 0.5 L/h in subjects 
with severe renal impairment. There are no data available for patients with CLCR <15 mL/min. 
 
Patients with mild hepatic impairment (classified as Child–Pugh A) exhibited only minor changes in 
the pharmacokinetics of rivaroxaban (i.e. an average of 1.2-fold increase in AUC), compared with the 
healthy control group. In patients with moderate hepatic impairment (classified as Child–Pugh B), 
there was an increase in rivaroxaban plasma concentrations and a prolonged elimination phase. In 
these patients, the AUC and Cmax were increased by 2.3- and 1.3-fold, respectively, compared with 
healthy subjects. In addition, the elimination half-life was prolonged by approximately 2 h compared 
with healthy subjects. 
 
Thus, in subjects with moderate to severe renal impairment and subjects with hepatic impairment 
(Child Pugh B), rivaroxaban plasma concentrations were significantly increased when compared with 
healthy subjects. In addition, FXa activity inhibition was significantly more pronounced and clotting 
tests showed prolongations compared with healthy subjects.  
 
Therefore subjects with known significant liver disease and with severe renal impairment (calculated 
<30 ml/min) will be excluded from this study.  
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Phase 2 Studies  
Currently, several Phase 2 studies have been completed evaluating the safety and efficacy of 
rivaroxaban compared with enoxaparin in the prophylaxis of VTE associated with total hip and total 
knee replacement surgery. In addition, one Phase 2 study has recently been completed comparing 
treatment with rivaroxaban to treatment with enoxaparin followed by 3 months of warfarin in subjects 
with symptomatic proximal venous thromboembolic disease. 
 
Venous Thromboembolism Prevention Studies  
In the Phase 2 dose-ranging studies ODIXa-HIP2 and ODIXa-Knee, 1,343 subjects were randomized 
to oral rivaroxaban at 2.5, 5, 10, 20, or 30 mg twice daily following hip or knee surgery, or 
subcutaneous enoxaparin (40 mg once daily starting 12 hours before hip surgery or 30 mg twice daily 
starting 12 hours after knee surgery), continuing until mandatory bilateral venography was performed 
5 to 9 days after surgery. The primary efficacy endpoint was a composite of DVT, PE, and all-cause 
mortality. The primary safety endpoint was major postoperative bleeding. The combined analyses 
from these 2 studies showed that the primary efficacy endpoint occurred in 21.6%, 22.9%, 16.1%, 
24.4%, and 19.3% of subjects receiving rivaroxaban 2.5, 5, 10, 20, and 30 mg twice daily, 
respectively, and 27.8% receiving enoxaparin (n=914). No significant dose-response relationship for 
efficacy was observed with rivaroxaban (P=0.39); this was potentially due to the efficacy achieved 
with the lower rivaroxaban doses. A significant dose response relationship was observed for major, 
postoperative bleeding with rivaroxaban (P<0.001), which occurred in 0.9%, 1.3%, 2.1%, 3.9%, and 
7.0% of subjects receiving rivaroxaban 2.5-, 5-, 10-, 20-, and 30-mg twice daily, respectively, and 
1.7% of subjects receiving enoxaparin (n=1,317). These studies demonstrated that rivaroxaban has a 
wide therapeutic window for the prevention of VTE following major orthopedic surgery, and, at doses 
of 2.5 to 10 mg twice daily, has similar efficacy and safety to the enoxaparin regimens. 
 
Venous Thromboembolism Treatment Study  
One Phase 2 study has been conducted in subjects with acute symptomatic DVT. This study (ODIXa-
DVT) was a prospective, randomized, double-blind (for 4 different rivaroxaban doses), active-
comparator controlled, multicenter, and multinational dose-finding study in 613 subjects with acute 
symptomatic DVT. The study assessed safety, tolerability, and efficacy of rivaroxaban at oral doses of 
10, 20, and 30 mg twice daily and 40 mg once daily compared with enoxaparin/VKA in the treatment 
and secondary prevention of VTE. Study drugs were administered for 12 weeks. The primary efficacy 
endpoint was the response (improvement=thrombus regression) to treatment as determined by 
compression ultrasonography (CUS) after 3 weeks of treatment. 
 
Thrombus regression as assessed by CUS (primary efficacy endpoint) was observed in 53%, 59%, 
44%, and 57% of subjects receiving rivaroxaban 10 mg twice daily, 20 mg twice daily, 40 mg once 
daily, and 30 mg twice daily, respectively, compared with 46% for enoxaparin/VKA. There was no 
statistical evidence of a trend in the dose–response relationship between rivaroxaban and the primary 
efficacy endpoint. 
 
The main safety endpoint in this study was the number of major bleeding events. The percentages of 
major bleeding events in the rivaroxaban dose groups ranged between 1.7 (10 and 20 mg twice daily 
and 40 mg once daily) and 3.3% (30 mg twice daily) compared with no events in the enoxaparin/VKA 
group; however, the differences between treatment groups were not statistically significant. It is 
important to note that there were no fatal bleedings or bleedings into critical organs in any of the 
treatment groups. This study supports evidence for the efficacy of rivaroxaban in the treatment of 
acute symptomatic DVT. The optimal net clinical benefit of rivaroxaban with regard to incidence rates 
of major VTE events and major bleeding events was obtained with rivaroxaban doses of 10 and 20 mg 
twice daily. 
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Safety Assessment Studies  
Comprehensive toxicological investigations of rivaroxaban have been performed. No 
clinicopathologic or histopathologic evidence of hepatotoxicity in any of the animal species tested 
(mice, rats, and dogs) has been observed.  
 
In the Phase 1 program, a total of 735 subjects have been exposed to rivaroxaban. Eighteen subjects 
treated with rivaroxaban had elevated laboratory values (aspartate aminotransferase [AST]/alanine 
aminotransferase [ALT], gamma-glutamyl transferase, total bilirubin, amylase/lipase) postdose. None 
of these subjects presented a signal indicative of liver injury due to rivaroxaban. Often the peak 
elevation occurred several days to 1 week after a single dose of rivaroxaban. Values returned to 
normal or pretreatment levels, regardless of study drug discontinuation. No clinical concerns were 
raised based on these findings.  
 
In the 4 completed Phase 2 VTE prophylaxis trials, a total of 2,232 patients had received rivaroxaban 
and 555 patients had received the comparator drug, enoxaparin. Three patients (0.2%) in the 
rivaroxaban group and 2 patients (0.5%) in the enoxaparin group had ALT levels 3 times greater than 
ULN plus total bilirubin levels 2 times greater than ULN during treatment. In these 5 cases the liver 
function test (LFT) abnormalities resolved spontaneously without discontinuing study drug. 
 
In conclusion, although ALT values 8 times greater than ULN and ALT values 3 times greater than 
ULN in combination with bilirubin values 2 times greater than ULN have been observed in 
rivaroxaban-treated patients in the Phase 2 VTE prophylaxis program, such elevations have also been 
observed in the enoxaparin group. These elevations have not led to any clinically significant effects 
during the clinical development program. 
 
Since currently approved anticoagulants (such as heparin and enoxaparin) and novel oral 
anticoagulants recently in development (e.g., ximelegatran) have been associated with LFT 
abnormalities, it would appear prudent to:  continue to monitor LFTs closely in the ongoing 
rivaroxaban clinical programs including this one and to routinely collect samples for LFT testing 
during the treatment phase. 
 
1.3 Warfarin 
 
Warfarin is a synthetic derivative of dicoumarol, that acts by inhibiting vitamin K epoxide reductase, 
an enzyme that recycles oxidized vitamin K1 to its reduced form after it has participated in the 
carboxylation of several blood coagulation proteins, mainly prothrombin and factor VII. Warfarin is 
indicated for the prophylaxis and/or treatment of VTE, PE, and thromboembolic complications 
associated with atrial fibrillation and/or cardiac valve replacement, and is indicated to reduce the risk 
of death, recurrent myocardial infarction, and thromboembolic events after myocardial infarction. The 
most serious risk associated with warfarin is hemorrhage in any tissue or organ. Treatment of each 
patient with warfarin is highly individualized and therefore, periodic determination of PT/INR is 
essential. 
 
1.4 Rationale for the study  
 
Patients with AF have a 5-fold increase in the risk of non-hemorrhagic stroke compared to patients in 
sinus rhythm. While oral VKAs can reduce the risk of stroke in such patients, the well known 
limitations (e.g., need for frequent monitoring of the level of anticoagulation), side-effects, and 
food/drug interactions of coumarin-derivatives provide a clinical opportunity for the development of 
safer, more effective, and simpler-to-use oral agents. Rivaroxaban has more predictable anticoagulant 
effect, does not require monitoring for blood tests, and has fewer drug/food interactions. If 
demonstrated to be as safe and effective as warfarin in this study, rivaroxaban would represent a 
potential alternative to VKAs in patients with AF.  
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This Phase 3 study is being conducted to demonstrate non-inferiority of rivaroxaban relative to 
warfarin (INR: 2.0 to 3.0, inclusive) in reducing the risk of stroke and/or SEE in subjects with 
documented non-valvular AF and in whom oral anticoagulation is indicated and planned for the 
duration of the study.  
 
1.5 Rationale for Dose Selection 
 
Rivaroxaban 
Taking into consideration results of the dose-ranging Phase 2 VTE treatment studies that showed once 
and twice daily doses from 20 mg per day to 60 mg per day to be approximately comparable for 
efficacy and safety, the lowest tested dose of 20 mg once daily is selected for further evaluation.  
Based on the expected differences in the pharmacokinetics between the populations of subjects with 
DVT and atrial fibrillation, it was decided to use a dose adaptation to 15 mg once daily for those 
subjects with moderate renal impairment at screening (defined as calculated CLCRbetween 30 and 49 
mL/min, inclusive). Based on pharmacokinetic modeling this dose adaptation results in the same 
exposure (AUC), and hence can be analyzed as a single-dose-arm.  
 
Warfarin 
 
The warfarin dose will be selected by the treating physician to titrate the INR to a target of 2.5 (range 
2.0 to 3.0, inclusive).  
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2 TRIAL OBJECTIVES AND HYPOTHESES 
 
The primary objective is to compare rivaroxaban to warfarin and to demonstrate that its efficacy is 
non-inferior to that of dose adjusted warfarin in patients with non-valvular atrial fibrillation with 
regard to the composite primary endpoint of stroke and systemic embolism.  
 
Hypothesis: Rivaroxaban is non-inferior to warfarin in the prevention of the composite endpoint of 
stroke and non-CNS systemic embolism in subjects with non-valvular atrial fibrillation.  
The principal safety end point is a composite of major and nonmajor clinically relevant bleeding 
events. Bleeding events involving the central nervous system that meet the definition of stroke will be 
adjudicated as hemorrhagic strokes and they will be included in both the primary efficacy and safety 
end points. 
Secondary Objectives  
1. To compare rivaroxaban to warfarin with regard to the composite clinical outcome of stroke, non-
CNS systemic embolism, and vascular death as well as each component separately.  
2. To compare rivaroxaban to warfarin with regard to the composite of MI, non-fatal stroke, non-fatal 
SEE, and death due to cardiovascular cause or bleeding.  
3. To compare the effects of rivaroxaban and warfarin with respect to disabling stroke (severity of 
strokes according to modified Rankin scale) and all-cause mortality 
4. To evaluate the safety of rivaroxaban vs. warfarin with respect to  
•Individual bleeding event categories,  
 
•All other clinical and laboratory safety assessments including liver enzyme and bilirubin 
abnormalities.  
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3 TRIAL DESIGN 
 
This is a randomized, double-blind, double-dummy, parallel-arm study assessing rivaroxaban and 
warfarin with titration based on central monitoring of the international normalized ratio (INR). 
Subjects will receive active rivaroxaban tablets and placebo warfarin tablets or placebo rivaroxaban 
tablets and active warfarin tablets. 
 
3.1 Details for the design of the trial 
 
The study will be divided into a screening period, a double-blind treatment period closing with a study 
end visit, and a post-treatment observation period. At the study end visit or at an early study 
medication discontinuation visit for premature discontinuation of study therapy, subjects will be 
transitioned from study drug to an open-label VKA or other appropriate therapy. Patients may 
discontinue study drug for any of the following reasons: safety concerns, pregnancy, stroke or 
systemic embolism, abnormal liver function, creatinine clearance <25 mL/min on 2 consecutive 
measurements, noncompliance, or the need for an excluded medication. 
 
At the end of the post-treatment observation period, a follow-up visit will occur. The duration of the 
treatment period for a given subject will depend on the time required to accrue 445 adjudicated 
primary efficacy endpoint events, i.e., stroke, non-CNS systemic embolism, in the per protocol 
population. As a result, the time on study drug will vary from subject to subject depending upon the 
time of the subject’s enrollment. The expected maximum duration of the study is 32 months. 
Approximately 14.834 subjects are expected to enroll in this study. 
Subjects will be qualified for the study within 15 days before randomization to allow adequate time for 
the site to review the inclusion and exclusion criteria for the prospective study participant. After 
meeting all study entry criteria, subjects will be randomized into treatment groups and begin study 
drug treatment. The randomization will take place with the use of an Interactive Voice Response 
System (IVRS) and subjects will be randomly assigned in a 1:1 ratio to 1 of the following 2 treatment 
groups:  
 Rivaroxaban 20 mg p.o. once daily plus warfarin placebo p.o. once daily titrated to a target 
sham INR of 2.5 (range 2.0 to 3.0, inclusive). Subjects with moderate renal impairment at 
screening (defined as calculated CLCR between 30 and 49 mL/min, inclusive) will have a 
dose adaptation to rivaroxaban 15 mg p.o. once daily  
 
OR  
 
 Warfarin p.o. once daily titrated to a target INR of 2.5 (range 2.0 to 3.0, inclusive) plus 
rivaroxaban placebo p.o. once daily  
 
Sham INR results will be generated by means of a validated algorithm reflecting the distribution of 
values in warfarin-treated patients with characteristics similar to those in the study population. The 
sham INRs will be based on real subject data that take previous treatment doses, age, and sex into 
account. A point-of-care coagulation testing device displays a code number that, when entered into the 
Interactive Voice Response System along with the subject's study identification number, is decoded 
and generates either the subject's real INR or a sham INR value, depending on the patient's blinded 
treatment. 
 
During the study, INR monitoring occurs as often as clinically indicated but no less frequently than 
every 4 weeks. An unblinded physician, not affiliated with the conduct of the study, will monitor the 
warfarin management to ensure clinical sites respond to values out of range. Finally, the time in 
therapeutic range for the patients treated with warfarin will be reported at the conclusion of the study. 
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While on study drug, unblinded INR measurements must not be performed except in case of a medical 
emergency.  
It is especially important to limit site personnel knowledge of any unblinded INR values to a minimum. 
 
Once a subject is determined to be eligible for the study, the subject will be instructed to discontinue 
their VKA (if applicable); in this case, unblinded INRs (i.e., not using the point-of-care device) should 
be performed every 1 to 2 days based on the initial INR.  
 
Randomization of the subject should occur as soon as possible when the INR is ≤3.0.Randomization 
should occur within 36 hours of the last unblinded INR. Once the subject’s eligibility for the study has 
been reconfirmed, the subject will be randomized (Day 1) and study drug will be dispensed. 
Subjects will return for visits at Week 1, 2, 4, and then every 4 weeks thereafter for the duration of the 
double-blind treatment period. A 12-lead electrocardiogram (ECG) and clinical laboratory tests will be 
performed annually. 
All randomized subjects will be followed until the study ends (445 adjudicated endpoint events 
reached followed by study closure activities) even if they did not take study drug or prematurely 
discontinued study drug. Every effort will be made to contact any subjects lost to follow-up and 
collect information on the occurrence of efficacy endpoint events and the reason for discontinuation. 
When the pre-specified number of adjudicated primary efficacy endpoint events has been reached in 
the per protocol population, the sites will be notified by the sponsor to schedule each subject still 
receiving blinded study medication for a study-end-visit. This visit should be completed as soon as 
possible, but within 30 days after site notification. At the study-end -visit, subjects will be transitioned 
from blinded study drug to an open-label VKA or other appropriate therapy and followed in the post-
treatment observation period. The post-treatment observation period ends with a follow-up visit, which 
will be performed approximately 30 days after the study-end-visit. Subjects who have previously 
prematurely discontinued study drug will be contacted for a final assessment of efficacy endpoint 
events within 30 days of site notification. 
An Executive Committee (EC) will be formed that has the overall responsibility for the conduct and 
reporting of the study. An independent Data Monitoring Committee (DMC) will be commissioned for 
this study, in order to monitor the progress of the study and to ensure that the safety of the subjects is 
not compromised. An independent blinded Clinical Endpoint Committee (CEC) will apply the 
protocol definitions and adjudicate and classify the following endpoints: stroke, non-CNS systemic 
embolism, death, myocardial infarction, TIA, major bleeding event, and non-major clinically relevant 
bleeding event. 
The study design is presented below: 
 
Figure 1 Plot summarizing the design of the study. 
. 
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 3.2 Committees 
 
3.2.1. Executive Committee  
The EC consists of members of the academic leadership of the study and 1 member from the 
sponsoring company. The EC will ultimately be responsible for the conduct of the study including 
addressing any Data Monitoring Committee recommendations and overseeing publication of the 
results.  
 
3.2.2. Steering Committee  
A Steering Committee will be formed consisting of members who are lead investigators from each 
country/region. The Steering Committee will advise and assist the EC with regard to the scientific and 
operational aspects of the study.  
 
3.2.3. Independent Data Monitoring Committee 
This study will be conducted under the auspices of an independent Data Monitoring Committee 
(DMC), which will monitor the progress of the study and ensure that the safety of subjects enrolled in 
the study is not compromised. The DMC will have a chairperson and include at least 2 cardiologists, a 
neurologist, as well as a statistician. This committee will review accumulating data on a regular basis, 
and may request to review partially unblinded or unblinded accumulating data. The DMC will make 
recommendations to the Executive Committee and Sponsor regarding the continuing safety of subjects 
currently enrolled and yet to be enrolled in the trial. At all times during the course of the study, the 
DMC may request access to unblinded data if needed. 
3.2.4 Clinical Endpoint Committee 
The Clinical Endpoint Committee (CEC), composed of experts in the relevant fields, will review, in a 
blinded manner, all reported study outcomes to provide consistency and validity in the assessment of 
outcomes. Their decisions will be based on blind clinical data. Their decisions will be used for the 
final statistical analyses. 
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 4 ETHICAL CONSIDERATIONS 
 
This study will be conducted in compliance with the protocol, the ethical principles set forth in the 
Declaration of Helsinki, the ICH Guideline E6 for GCP and applicable regulatory requirement(s). 
Good clinical practice (GCP) is an international ethical and scientific quality standard for designing, 
conducting, recording, and reporting research studies that involve the participation of human subjects.  
Compliance with this standard provides public assurance that the rights, safety, and well-being of 
study subjects are protected, consistent with the principles that have their origin in the Declaration of 
Helsinki, and that the clinical study data are credible. 
 
4.1 Institutional Review Board/Independent Ethics Committee  
 
The protocol and any amendments, the Investigator’s Brochure, the subject informed consent and any 
information on compensation for study-related injuries or payment to subjects, will receive IRB/IEC 
approval prior to initiation of the study. During the study the investigator will send to the IRB any 
reports of adverse events that are serious, unlisted, and associated with the investigational drug and 
any new information that may adversely affect the safety of the subjects or the conduct of the study.  
Study personnel involved in conducting this study will be qualified by education, training, and 
experience to perform their respective task. 
 
4.2 Informed Consent   
 
Before a subject’s participation in the study, it is the Investigator’s responsibility to obtain freely given 
consent, in writing, from the subject or a legally acceptable representative after adequate explanation 
of the aims, methods, anticipated benefits, and potential hazards of the study and before any protocol-
specific procedures or any study drugs are administered. 
 The written ICF should be prepared in the local language(s) of the potential subject population. The 
informed consent should be approved by the IRB prior to being provided to potential subjects. 
The written informed consent form and any other written information to be provided to subjects 
should be revised whenever new information becomes available that may be relevant to the subject’s 
consent. Any revisions to the written informed consent form and/or to other written information 
provided to the subject should be approved by the responsible IRB in advance of use. 
Subjects unable to give their written consent (e.g., stroke subjects, or subjects with severe dementia) 
may only be enrolled in the study with the consent of a legally acceptable representative. The subject 
must also be informed about the nature of the study to the extent compatible with the subject’s 
understanding. 
 
If a subject or a subject’s legally acceptable representative is unable to read, an impartial witness 
should be present during the entire informed consent discussion. 
Subjects may withdraw consent from participation in the study at any time. In the event a subject 
withdraws consent to receive study drug, the site may (with the subject’s agreement) continue to 
contact the subject, general practitioner, and any other physician or medical care provider for the 
collection of outcome and survival follow-up  data. 
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4.3 Subject Confidentiality 
 
The Investigators and the Sponsor will preserve the confidentiality of all subjects taking part in the 
study, in accordance with GCP and local regulations. 
The Investigator must ensure that the subject’s anonymity is maintained. On the eCRFs or other 
documents submitted to the Sponsor or the CRO, subjects should be identified by a unique subject 
identifier as designated by the Sponsor. Sponsor personnel whose responsibilities require access to 
personal data should agree to keep the identity of study subjects confidential. 
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5 SELECTION OF SUBJECTS-STUDY POPULATION 
 
The study population will consist of adult subjects with non-valvular atrial fibrillation who are at 
moderate to high risk for stroke and non-CNS systemic embolism. 
 
5.1 Inclusion criteria 
 
For entry into the study, the following criteria MUST be met.  
1) Age ≥18 years  
 
2) In atrial fibrillation or atrial flutter not due to a reversible cause and documented by  
ECG at the time of enrollment or within 30 days before randomization 
 
3) Subjects with newly diagnosed atrial fibrillation are eligible provided that: 
 there is ECG evidence on 2 occasions 24 hours apart demonstrating atrial fibrillation  
 cardioversion is not planned 
4) There must be evidence that the atrial fibrillation is NOT valvular 
5) History of prior ischemic stroke, TIA or non-CNS systemic embolism believed to be cardioembolic 
in origin OR has 2 or more of the following risk factors:  
 Age 75 years or older 
 Diabetes mellitus 
 Hypertension requiring pharmacological treatment 
 Either symptomatic congestive heart failure within 3 months or left ventricular dysfunction 
with an LV ejection fraction (LVEF) ≤35 % by echocardiography, radionuclide study or 
contrast angiography  
 
6) The number of subjects without a prior stroke, TIA or non-CNS systemic embolism and only 2 risk 
factors will be limited by the IVRS to approximately 10% by region of the total number of subjects 
enrolled. 
 
7) Female subjects must be postmenopausal (for at least 2 years), surgically sterile, abstinent, or, if 
sexually active, they must be using an adequate method of contraception(e.g. oral contraceptives, 
intrauterine device, double-barrier method) to avoid pregnancy throughout the treatment period of the 
study or for 2 weeks after the last dose of study medication. 
8) All subjects must provide signed written informed consent 
 
5.2 Exclusion criteria 
 
Potential subjects who meet any of the following criteria will be excluded from participating in the 
study:  
 
1. hemodynamically significant mitral stenosis 
2. prosthetic heart valve  
3. Atrial fibrillation or flutter due to reversible causes (e.g. thyrotoxicosis, pericarditis) 
4. Active infective endocarditis 
5. Planned cardioversion 
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6. Increased bleeding risk that is believed to be a contraindication to oral anticoagulation, 
including but not limited to: 
 history of intracranial hemorrhage, known intracranial neoplasm or aneurysm 
 clinically significant gastrointestinal bleeding within 6 months before 
randomization 
 chronic hemorrhagic disorder 
 Platelet count ≤100,000/ mm3 
7.  Planned major surgery 
8.  Required treatment with aspirin > 165 mg/day 
9.  Simultaneous treatment with both aspirin and a thienopyridine (e.g., clopidogrel) 
10.  Severe renal insufficiency ( calculated creatinine  clearance < 30 mL/min) 
11. Known significant liver disease (e.g., acute clinical hepatitis, chronic active hepatitis, 
cirrhosis), or ALT >3 x the ULN  
12. Persistent, uncontrolled hypertension (systolic BP > 180 mm Hg, or diastolic BP > 100 mm 
Hg)  
13. Active alcohol or drug abuse, or psychosocial reasons that make study participation 
impractical  
14. Hemoglobin < 9 g/dL 
15. Systemic treatment with a strong inhibitor of cytochrome P450 3A4, such as ketoconazole  
16. Treatment with a strong inducer of cytochrome P450 3A4, such as rifampin/rifampicin 
17. Pregnancy or breast-feeding 
 
5.3 Discontinuation of treatment-Withdrawal of Subjects 
 
Individual subjects may prematurely discontinue study drug. Reasons for study drug discontinuation 
are:  
 safety concerns (e.g adverse event, life threatening bleeding, abnormal liver function, 
creatinine clearance <25 mL/min on 2 consecutive measurements) 
  pregnancy  
 stroke or systemic embolism  
 noncompliance with study drug 
 the need for an excluded concomitant medication 
 
A subject will be withdrawn from the study for any of the following reasons: 
 withdrawal of informed consent form 
 death 
 lost to follow-up 
In case a subject is lost-to-follow-up, every possible effort must be made by the study site personnel to 
contact the subject to obtain complete data and determine the reason for withdrawal. This reason 
should be documented on the CRF and in the source document. 
 
Subjects, who discontinue treatment before the end of the study, and those who are withdrawn from 
the study, should have a follow-up visit approximately 30 days after the study drug discontinuation 
visit and they will be contacted every 3 months until the study ends to assess efficacy endpoint events. 
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6 RANDOMIZATION AND BLINDING 
 
Central randomization will be implemented in conducting this study. At the time of enrollment, each 
subject will be assigned a unique sequential subject number by the IVRS (interactive voice response 
system) and a treatment code, which will dictate the treatment assignment for that subject. The IVRS 
will be available 24 hours per day, seven days a week. The subject number will consist of a unique 5 
digit number which is assigned sequentially within the study (starting with 00001) by the IVRS. This 
number will be used for identification throughout the study and will not be used for any other subject. 
Subjects will be randomly assigned in a 1:1 ratio (rivaroxaban to warfarin) to 1 of 2 treatment groups 
and the randomization will be stratified by country, prior VKA use (defined as VKA use for 6 weeks 
or longer at the time of screening), and CHA2DS2-VASc risk score. So the IVRS will then also assign 
a medication kit (and subsequent medication kits) that matches the treatment code to which the subject 
has been randomized.  
The investigator will not be provided with randomization codes. The codes will be maintained within 
the IVRS, which has the functionality to allow the investigator to break the blind for an individual 
subject. 
 
This study has a double-blind and a double-dummy design. Neither the subjects nor any of the 
Investigators or Sponsor staff involved in the treatment or clinical evaluation of the subjects will be 
aware of the treatments received. There will be an independent DMC to monitor the data (bleeding 
AEs, liver enzymes and bilirubin abnormalities, SAEs, stroke, SEE) in an unblinded manner on a 
periodic basis. An independent statistician, not otherwise involved in the study, will prepare and 
provide the required reports to the DMC. 
 
The blind should be broken only if specific emergency treatment would be dictated by knowing the 
treatment status of the subject. If for any reason, the Investigator needs to become unblinded to the 
treatment of a subject, he/she will make every attempt to first call the sponsor and discuss the need for 
unblinding and obtain agreement. If the investigator is unable to contact the sponsor, the investigator 
may in an emergency determine the identity of the treatment by telephoning IVRS. The sponsor must 
be informed as soon as possible by the investigator. Efforts should be made to limit access to 
knowledge of the treatment assignment to only those individuals who need to know the information 
and the subject should continue in the study.  
Special bl inding procedures  
As it has already been stated, in order to ensure the study blinding, a double-dummy technique will be 
used so that similar dosing procedures can be followed in both treatment arms. This means that 
subjects randomly assigned to treatment with rivaroxaban will also receive a placebo that is identical 
in appearance to warfarin, whereas subjects randomly assigned to treatment with warfarin will also 
receive a placebo that is identical in appearance to rivaroxaban. 
Rivaroxaban and its matching placebo will be taken once daily as a fixed dose. Warfarin and its 
matching placebo will be dose-adjusted based on either real or sham INR results, respectively. To 
accomplish this, all INR measurements will be performed using uniform POC (point of care) devices 
supplied to all study sites. The INR results generated by the POC device will be embedded in a “code 
number” and reported to a central IVRS along with the subject's study identification number. This 
code number is decoded by the Interactive Voice Response System, and either the subject's real INR 
or a sham INR value is generated, depending on the patient's blinded treatment. 
 
In other words, for subjects randomized to warfarin, the true INR will be disclosed to allow the 
warfarin dose to be adjusted to maintain the INR between 2.0 and 3.0. Sham INR values will be given 
for subjects randomized to rivaroxaban to mimic variations expected for subjects on warfarin, so as to 
allow adjustments to the dose of placebo to match warfarin. 
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The measurement of the subject’s INR and reporting in an unblinded fashion will NOT be permitted 
during the treatment period. The study site personnel should use ONLY the study-provided POC 
device for INR assessments at all times after a subject begins study drug treatment. 
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 7 STUDY PROCEDURES 
 
The study is divided into 3 periods: a screening period, a double blind treatment period and a post-
treatment observation period. All randomized subjects will be followed until the study ends, even if 
they did not take study drug or prematurely discontinued study drug. 
7.1 Screening period 
 
As part of study qualification which takes place before randomization, potential subjects will have the 
study risks and benefits explained to them, the associated ICF reviewed with them, and all questions 
answered for them. Before the performance of any protocol-specific procedure, written informed 
consent should have been obtained by the investigator. 
Screening procedures will be performed within 15 days before randomization. The investigator should 
obtain relevant medical history and vital signs and perform physical examination. A 12 lead ECG and 
clinical laboratory tests (including  urine pregnancy test ) should also be performed. 
The results of all screening procedures must be reviewed before randomization to ensure that all 
inclusion criteria and none of the exclusion criteria are met. 
Eligible subjects will be instructed to return for a baseline visit (Day 1) on the day of planned 
randomization. Subjects who are on chronic therapy with a VKA must discontinue it once eligibility is 
confirmed; these subjects must have their randomization (Day 1) visit performed as soon as possible 
when the INR is ≤3.0 
 
7.2 Treatment period 
 
7.2.1. Day 1 –randomization 
Eligible subjects will be randomized to study medication using an IVRS as described in section 
6(Randomization and blinding) and study drug will be administered. The subjects should start taking 
study drug with food in the evening of the same day. 
 
7.2.2. Monthly visits  
Subjects will return for visits at week 1, 2, 4 and then every 4 weeks during the double-blind treatment 
period. (Additional interim visits may be scheduled, at the Investigators discretion, if necessary for 
INR monitoring) 
During these visits: 
 the INR should be assessed using the point of care device provided by the Sponsor for 
adjustment of warfarin (or placebo-to-match warfarin) doses(instructions for INR monitoring 
are provided in sections 3, 6 and 8) 
 adverse events should be recorded 
 efficacy endpoint events should be assessed 
 study drug should be dispensed, as needed 
 unused study drug tablets should be counted 
 targeted concomitant medications should be recorded  
 vital signs should be recorded 
 Liver function tests-SGOT, SGPT, γgt, ALP, Total bilirubin- should be performed on week 4 
and every 4 weeks thereafter 
 A 12 lead ECG will be performed annually 
7.2.3. Study drug discontinuation visit 
Individual subjects may prematurely discontinue study drug. Reasons for study drug discontinuation 
are: safety concerns, life threatening bleeding, pregnancy, stroke or systemic embolism, abnormal liver 
function, creatinine clearance <25 mL/min on 2 consecutive measurements, noncompliance, the need 
for an excluded medication or withdrawal of informed consent. 
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 They should have a follow-up visit approximately 30 days after the study drug discontinuation visit 
and they will be contacted every 3 months until the study ends to assess efficacy endpoint events. 
 
In case a subject is lost-to-follow-up, every possible effort must be made by the study site personnel to 
contact the subject to obtain complete data and determine the reason for withdrawal. This reason 
should be documented on the CRF and in the source document. 
 
 
7.2.4. Study end visit 
The study end visit will occur within 30 days after the prespecified number of adjudicated primary 
endpoint events has occurred, and is defined as the last visit in the double-blind treatment period for 
subjects on study drug at that time. All randomized subjects, including those who temporarily 
interrupted or discontinued study drug, will have a study end Visit. The study end visit activities 
include: 
 physical examination, vital signs, 12-lead ECG 
 Record AEs and endpoint events 
 Record date/time of final dose of study drug 
 Contact IVRS to record subject as having completed study end Visit 
 
After the final dose of study drug, the Investigator at his/her discretion will prescribe open-label 
antithrombotic therapy as per local guidelines. When subjects transition from blinded study drug to 
open-label warfarin (or other VKA) at the final visit, it is important to maintain the study blind to 
avoid the introduction of bias in the ascertainment of study endpoints. For this reason no INR 
measurements should be performed in the first three days after the final dose of blinded study drug. 
7.3 Post-treatment observation period- follow-up visit 
 
After the study end visit or Study drug discontinuation visit, there will be an observation period to 
follow subjects after transition from study drug to open-label VKA or other appropriate therapy. 
Subjects will return to the clinic for a follow-up visit approximately 30 days after the permanent 
discontinuation of study drug. 
At the follow-up visit the Investigator will:  
•Assess for SAEs (until 30 days after the last dose of double-blind study drug)  
•Assess for outcomes (death, stroke, systemic embolism, myocardial infarction) 
 
7.4 Efficacy Assessments 
 
7.4.1 Primary Efficacy Assessments 
The primary efficacy endpoint of the study will be the time to the first occurrence of confirmed stroke 
(hemorrhagic, ischemic or of unspecified type) or systemic embolism. An independent blinded 
Clinical Endpoint Committee will apply the protocol definitions and adjudicate and classify the 
following endpoints: 
Stroke: Stroke is defined as an abrupt onset of focal neurological symptoms resulting from a presumed 
cerebrovascular cause and lasting at least 24 hours, which are not due to a readily identifiable cause 
such as a tumor or seizure.  
If an event matching this definition lasts less than 24 hours it will be considered a TIA. 
It is strongly recommended that an imaging procedure such as a CT scan or MRI be performed. All 
strokes will be classified by the CEC as ischemic, hemorrhagic or type uncertain. 
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Subjects who die within 30 days of the onset of the stroke will be regarded as having had a fatal 
stroke. 
 
Non-CNS systemic embolism: is defined as an acute vascular occlusion of an extremity or organ, 
documented by means of imaging, surgery, or autopsy. 
 
7.4.2 Secondary Efficacy Assessments 
Myocardial infarction: The following criteria satisfy the diagnosis for an acute or evolving MI in an 
appropriate clinical context: 
•elevation of CK-MB or Troponin T or I ≥2 ×the ULN, or  
 
•if no CK-MB or troponin values are available, a total CK ≥2×ULN, or  
 
•new, significant (≥0.04 s) Q waves in ≥2 contiguous leads 
 
Vascular Death: This category includes cardiac deaths (e.g., cardiogenic shock, arrhythmia/sudden 
death, cardiac rupture) and other cardiovascular deaths (stroke, pulmonary embolism, ruptured aortic 
aneurysm or dissection) 
7.5 Safety Assessments 
 
The principal safety end point is a composite of major and non-major clinically relevant bleeding 
events 
 
Major Bleeding: clinically overt bleeding accompanied by a decrease in the hemoglobin level of at 
least 2 g per deciliter or transfusion of at least 2 units of packed red cells, occurring at a critical site, or 
resulting in death 
 
Non-major clinically relevant bleeding: clinically overt bleeding that does not satisfy the criteria for 
major bleeding and that leads to hospital admission, physician-guided medical or surgical treatment, 
cessation of study treatment or any other change in antithrombotic therapy. 
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 8 GUIDELINES FOR SUBJECT MANAGEMENT 
 
8.1 Invasive Procedures and Surgery 
 
It is anticipated that subjects enrolled in this clinical study may require invasive procedures. Study 
drug may be interrupted as necessary for these invasive procedures or as medically needed, taking into 
account the risk to the subject. For subjects with an intermediate or high risk of thromboembolism,   
warfarin/warfarin placebo should be discontinued approximately 4 days in advance of the procedure 
and rivaroxaban/rivaroxaban placebo approximately 2 days before. INRs using the point-of-care 
device should be performed daily or at the discretion of the investigator. When the INR is ≤1.5, the 
elective procedure may be performed. The physician may consider administration of low dose 
unfractionated heparin or prophylactic dose LMWH (e.g., enoxaparin 40 mg subcutaneous injection 
daily) beginning 2 days preoperatively. When hemostasis is secure and the subject is able to safely 
ingest oral medication, study drug should be resumed and daily INRs using the point-of-care device 
should be performed. 
For urgent or emergent invasive procedures, when waiting 4 - 5 days is not an option, management 
will in part depend on the randomized treatment assignment (warfarin or rivaroxaban) and unblinding 
may be necessary. 
 
8.2 Bleeding events 
 
Bleeding is of special interest because such events are a known concern associated with anticoagulant 
therapy including rivaroxaban and warfarin. All bleeding events either reported by the subject or 
observed by the Investigator should be recorded on the CRF, along with the date and time of onset. 
Clinically overt bleeding events requiring medical attention will be adjudicated by an independent and 
blinded Clinical Endpoint Committee. 
For subjects with minor bleeding, study drug may or may not be held at the discretion of the local 
physician and investigator, after a risk/benefit determination has been made. 
 
However, if a subject has a clinically significant bleeding event during study treatment, the study 
drugs should generally be held (rivaroxaban has a half time of 5 to 13 hours) and the following routine 
measures could be considered:  
 
 Volume resuscitation, and transfusion of blood products as appropriate  
 Warfarin can be reversed more quickly by giving oral or intravenous vitamin K, and/or with 
fresh frozen plasma 
 
 
There is no reversal agent for rivaroxaban. Given its half-life (5 - 13 hours), however, the 
anticoagulant effect of rivaroxaban abates in 24 - 48 hours. 
 
8.3 Treatment Guidelines for Jaundice, Elevated LFTs  
 
Liver function is another area of special interest. If at any time during the treatment period a subject’s 
liver function test (LFT) results show elevated ALT> 3 ULN and/or total bilirubin > 2 ULN, the 
following laboratories should have been obtained/retested  within the subsequent 5 days: : ALT, AST, 
total bilirubin, direct bilirubin, alkaline phosphatase, CPK . The treating physician may continue the 
study drug during this time. If the repeat value is lower, weekly ascertainment of ALT, AST, total and 
direct bilirubin, and alkaline phosphatase will be performed until the ALT is <3 x ULN. If the repeat 
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ALT ≥3x ULN AND the total bilirubin is ≥2 x ULN and this persists for more than one month, then 
study medication must be discontinued and hepatitis screen (anti-HAV, HbsAg, anti-HBc, anti-HBs 
and anti-HCV) and abdominal ultrasound have to be performed. 
8.4 Treatment Guidelines for patients with renal impairment 
 
As it has already been mentioned, subjects with severe renal insufficiency (calculated creatinine 
clearance < 30 mL/min) will be excluded from the study. 
Subjects with moderate renal impairment at screening (defined as calculated creatinine clearance 
[CLCR] between 30 and 49 mL/min, inclusive) will have a dose adaptation to rivaroxaban 15 mg p.o. 
once daily. 
If the calculated CLCR becomes <25 mL/min (confirmed by repeat assessment) during the study, then 
study medication should be discontinued. 
 
For subjects who start with a calculated CLCR of ≥50 mL/min and the CLCR decreases to below 50 
mL/min during the study, no dose adjustment will be performed. 
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 9 INFORMATION ABOUT TREATMENTS ADMINISTERED 
 
9.1 Study drugs description-drug accountability 
 
The Investigator must ensure that the Investigational Product will be used only in accordance with the 
protocol. Subjects will be randomly assigned to 1 of 2 treatment groups:  
 
• Rivaroxaban 20 mg p.o. once daily plus warfarin placebo p.o. once daily titrated to a target sham 
INR of 2.5 (range 2.0 to 3.0, inclusive). Subjects with moderate renal impairment at screening (defined 
as calculated CLCR between 30 and 49 mL/min, inclusive) will have a dose adaptation to rivaroxaban, 
15 mg p.o. once daily  
OR  
• Warfarin p.o. once daily titrated to a target INR of 2.5 (range 2.0 to 3.0, inclusive) plus rivaroxaban 
placebo p.o. once daily  
 
Subjects should be instructed to take the study drug in the evening with food. 
 
The study drugs will be supplied by the Sponsor and they should be stored at room temperature (22-25 
ºC) in a secure, limited-access storage area, protected from light .They will be sent to the 
investigational sites, and the Investigator will be responsible for dispensing them, providing the 
subjects with sufficient study drug until the next scheduled study drug dispensing visit. Subjects must 
be instructed to return all original containers, whether empty or containing study drug. Returned study 
drug must not be dispensed again, and should be disposed of according to the sponsor’s instructions. 
9.2 Concomitant Therapy 
 
All medications taken by each subject will be recorded on the CRF. 
 9.2.1 Restricted agents: 
 It is strongly encouraged to restrict the dose of aspirin (if indicated) to ≤100 mg daily, 
although higher doses are permitted for a strong clinical indication (e.g., development of an 
acute MI). 
 Chronic use of non-steroidal anti-inflammatory drugs (more than 10 consecutive days) should 
be avoided 
 Concomitant use of both aspirin (≤165 mg/day) and a thienopyridine (e.g. clopidogrel) 
together with study drug should be avoided .At the time of acute coronary syndrome the 
decision to employ dual antiplatelet therapy in subjects on study drug may arise. Because 
there are only few data from randomized clinical trials of dual anti-platelet therapy in the 
setting of oral anticoagulation, and there is a heightened concern regarding bleeding, this 
decision should be made carefully by the investigator, after having weighted the risks and the 
potential benefits. 
 
 
9.2.2 Prohibited Therapy 
The following drugs CANNOT be used during the treatment period, unless no alternative therapy is 
clinically suitable. In case any of the following medications is clinically necessary, the study drug 
should be temporarily interrupted:  
 Fibrinolytic agents,  if required to treat acute MI or PE, require study drug interruption 
 Systemic treatment with a strong inhibitor of cytochrome P450 3A4, such as atazanavir, 
clarithromycin or ketokonazole 
 Treatment with a strong inducer of cytochrome P450 3A4, such as rifampin/rifampicin,  
phenytoin or phenobarbital 
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 10 STATISTICAL CONSIDERATIONS 
 
The primary efficacy endpoint will be the time to first occurrence of confirmed ischemic stroke, 
hemorrhagic stroke, stroke of unspecified type or systemic embolism. 
H0: RR ≥∆ 
Versus 
  
H1: RR < ∆,  
 
Where: 
 RR represents the risk of rivaroxaban relative to warfarin   
  H0 (the null hypothesis): rivaroxaban is less effective than vitamin K antagonists in reducing 
thromboembolic events (it is inferior). 
 H1 (the alternative hypothesis): rivaroxaban is at least as effective as vitamin K antagonists in 
reducing thromboembolic events (it is not inferior). 
 
10.1 Sample size determination 
 
10.1.1 Noninferiority margin 
A key aspect of developing the adequate sample size for this trial is arriving at the appropriate non-
inferiority margin 
 
Noninferiority trials without a placebo arm often require an indirect statistical inference for assessing 
the effect of a test treatment relative to the placebo effect or relative to the effect of the selected active 
control treatment. The indirect inference involves the direct comparison of the test treatment with the 
active control from the noninferiority trial and the assessment, via some type of meta-analyses, of the 
effect of the active control relative to a placebo from historical studies. 
 
Warfarin has been studied in 6 different placebo controlled randomized trials in subjects with AF. 
These studies are described by J. Lawrence along with the details of a meta-analysis for the studies. In 
the 6 trials, the overall Relative Risk (RR) for warfarin vs placebo was 64% (95% CI 47%-76%). Each 
of the trials was terminated early owing to efficacy or results of publications demonstrating the 
superiority of warfarin to placebo. These early terminations may have led to some degree of 
overestimation of the magnitude of treatment effect and resulted in wide CIs for the estimates in each 
study.  
Although the efficacy and safety of warfarin treatment in AF are consistent across the historical 
placebo-controlled trials, an equally important question is how relevant these trials are to 
contemporary clinical practice. Older trials were conducted in the context of very different care (such 
as less emphasis on blood pressure control), with different standards for warfarin use (such as lack of 
standard target INR across trials), with combination of open-label and blinded designs, and with 
differing primary outcomes, durations of treatment, and quality of follow-up. Thus, although the 
overall data show a clearly substantial benefit to VKA versus placebo in preventing stroke, the exact 
degree of benefit and confidence thereof are uncertain, which provides an unstable foundation for 
establishing the degree of benefit one needs to preserve with an alternative antithrombotic. 
All of these factors argue that standards should be high in noninferiority trials, which necessarily use 
historical controls to establish the treatment effect to be shown to be preserved.  
In the case of warfarin for AF, the treatment effect from prior trials is robust and consistent even given 
their limitations, thus providing high confidence in the benefits of warfarin. The Relative Risk 
Reduction (RRR) of warfarin compared with placebo in these trials using a random effects model was 
0.36 (95% CI 0.24-0.53), such that the inverse of the upper boundary (i.e., control compared with 
warfarin) is 1.88 (1/0.53).   
Institutional Repository - Library & Information Centre - University of Thessaly
09/12/2017 13:10:11 EET - 137.108.70.7
The noninferiority margin is determined by halving the control effect, based on a historical placebo-
controlled trial. This type of “discounting” is applied to protect against lack of “constancy”, that is, 
conditions in the planned non-inferiority study have changed from the historical meta-analysis data. 
To establish that at least half of the warfarin effect is preserved, the noninferiority margin is 1.38 (i.e., 
the margin is the midpoint between 1.0 and 1.88 on a log scale rather than linear scale because the 
primary parameter estimated is the logarithm of the relative risk) 
In other words if we want to show that rivaroxaban maintains at least half of a conservative 
estimate of the historical benefit of warfarin relative to placebo, then the upper limit of a two-
sided CI for the relative risk of rivaroxaban versus warfarin must be less than 1.38.  
 
10.1.2   Determination of sample size-number of events 
When the end point is measured as the time to the event rather than the event rate, the number of 
events needed for a 1-side level-α test to detect a hazard ratio ρ with 1−β power is then given by: 
 
So in this case if we want a 95% confidence interval and the power is 90%, we have: 
 D=4 (1,96+1,28/ln (1,38))2=404,81  
So based on the above assumptions, we need at least 404,81 primary efficacy endpoints. Increasing 
this number by approximately 10% to 445 will provide a more robust number of events to assess 
consistency across important subgroups. 
The total number of randomized subjects for obtaining 445 adjudicated events from the per protocol 
population is calculated based on the following assumptions: 
 Warfarin treatment group event rate of 2.3% per patient-year (This event rate was adjusted for 
patients with high risk that are likely to present according to the inclusion criteria) 
 The mean time on treatment(either warfarin or study drug) and follow up will be 18 
months(1,5 years) 
 Expected dropout (withdrawal of consent, lost to follow-up, premature discontinuation of 
study drug) rate of 15%. 
 
This means we need 445/0,023 =19.348 patient-years or (due to the fact that the mean time on 
treatment (either warfarin or study drug) and follow up is expected to be 18 months (1,5 years)), we 
need 19348/1.5=12899 patients. 
Moreover, if we want to compensate for the expected dropout as mentioned above, we have to 
increase this number by 15%.So finally we need at least 14.834 patients for an expected number of 
445 primary endpoints. 
 
10.2 Analysis Populations 
 
The per protocol population includes all randomized patients excluding those who have specific pre-
defined major protocol deviations that occur by the time of enrollment into the study or while they are 
on treatment and before they experience a primary efficacy endpoint event. The protocol deviations 
mentioned above include: 
 No proper informed consent 
 Inadequate documentation of atrial fibrillation at the time of  enrollment into the study  
 Prosthetic heart valve 
 Receiving study medication different from that assigned by the IVRS 
 Not receiving any study medication during the double-blind treatment period  
 
Institutional Repository - Library & Information Centre - University of Thessaly
09/12/2017 13:10:11 EET - 137.108.70.7
On treatment: A study subject is considered to be on treatment during the period from the first double-
blind study medication administration until the final dose of study drug, the study-end-visit or death, 
whichever comes first. During a study drug interruption or discontinuation, the subject is considered at 
risk during the first two days, even though the subject is not on study drug, to allow consideration for 
any carryover effects.   
Intention-to-treat population includes all randomized patients in the groups to which they were 
randomly assigned, regardless of their adherence to the entry criteria, regardless of the treatment they 
actually received, and regardless of subsequent withdrawal from treatment or deviation from the 
protocol. So everyone who will be randomized in the trial will be considered to be part of the trial 
regardless if he or she has completed the trial. 
 
All ITT analyses will be performed based on the on-treatment ITT population and will evaluate time 
while on study drug till 2 days after permanent discontinuation. 
 
Safety Analysis population: All randomized subjects who receive at least one dose of randomized 
study drug. Analyses will be based on the randomized treatment unless a subject inadvertently 
receives the incorrect drug during the entire study, in which case, the subject will be grouped 
according to the treatment actually received. 
All safety analyses will be performed based on the safety population while on treatment. 
The ITT population, while on treatment and the Per Protocol population will be included in the 
primary efficacy analysis for non-inferiority. The Per Protocol population will be included in the 
secondary efficacy analyses for non-inferiority. The ITT population, while on treatment will be 
included in the secondary efficacy analyses for superiority. 
The safety analysis population will be included in the safety analyses. 
All analyses will be performed on observed data only. No missing data will be imputed. Only events 
confirmed by the Clinical Endpoint Committee will be included in the analyses. Data on subjects who 
do not reach the primary endpoint will be censored at the earlier of their death date (when death is not 
part of the endpoint) or last contact date (for subjects who withdraw consent to be followed up or are 
lost to follow-up).  
10.3 Primary Efficacy Analysis 
 
The primary hypothesis is that rivaroxaban will be noninferior to warfarin for the prevention of stroke 
or systemic embolism. The ITT population, while on treatment, and the Per Protocol population will 
be included in the efficacy analyses for non-inferiority. 
 
The time to first event is defined as the time (years) at risk from the initial dose of study drug to the 
first event experienced by a subject while at risk. The subject is at risk while taking study drug. During 
a study drug interruption or discontinuation, the subject is considered at risk during the first two days 
even though the subject is not on study drug to allow consideration for any carryover effects. The 
events occurring during such study drug interruptions/discontinuations (except for events occurring 
during the first two days) will not be included in the primary analysis. 
For subjects who do not experience an event while at risk, the time to first event will be censored at 2 
days after the final dose, the study-end-Visit or the subject’s last assessment while at risk. 
To ascertain non-inferiority, it will be necessary to demonstrate that the rivaroxaban event rate for the 
primary endpoint is not substantially higher than the warfarin event rate as measured by the hazard 
ratio (or relative risk) of rivaroxaban relative to warfarin. So based on time from randomization to the 
first occurrence of a primary efficacy endpoint event, the objective of the primary efficacy analysis is 
to establish that rivaroxaban is noninferior to warfarin by a non-inferiority margin of 1.38 in terms of 
risk ratio. 
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The time to first event will be analyzed using the Cox Proportional Hazards Model with treatment 
as a covariate and a 2-sided 95% confidence interval for the hazard ratio rivaroxaban/warfarin. If the 
upper limit of this 2-sided confidence interval is below the non-inferiority margin of 1.38, then non-
inferiority of the study drug can be declared.  
Additional analyses will be made using 3 stratification factors, one at a time: region-country, prior 
VKA status (experienced or naïve) and history of prior stroke. 
If non-inferiority for the primary efficacy endpoint on the per-protocol population is satisfied, then 
non-inferiority for the primary efficacy endpoint on the ITT population while on treatment will be 
tested, using the same approach described above. 
 
Furthermore, cumulative event rates of the primary efficacy endpoint over time will be estimated 
using the Kaplan-Meier method. 
 
10.4 Subgroup Analyses 
 
In order to test for homogeneity of treatment effect across subgroups as far as the primary efficacy 
endpoint is concerned, the following subgroups will be examined using the Cox proportional Hazards 
Model: 
 Geographic Region 
 CHA2DS2-VASc Score 
 History of prior stroke or TIA 
 Sex 
 Race (Caucasian, Asian, Black) 
 Renal function (CLCR<50 or  ≥50 ) 
 Prior VKA use (defined as VKA use for 6 weeks or longer at the time of screening) 
 Age (≤64, 65-75, >75) 
10.5 Secondary Efficacy Analysis 
 
Secondary efficacy endpoints will be analyzed based on the Intention-to-treat population, while on 
treatment. If non-inferiority for the primary efficacy endpoint is satisfied, then non-inferiority for the 
secondary efficacy endpoints on the per protocol population will be tested. The non-inferiority margin 
will be the same (1,38) as that for the primary efficacy non-inferiority analysis. 
 
The first secondary endpoint is the composite of stroke, non-CNS systemic embolism, and vascular 
death. The time to first event is defined as the time (years) from the day of randomization to the first 
event experienced by a subject. The time to first event (an event of stroke, SEE, or death) will be 
estimated by a Kaplan-Meier estimate and will be compared between rivaroxaban and warfarin using 
Cox Proportional Hazards Model at a significance level of 95%. 
 
The other secondary endpoint is the composite of MI, non-fatal stroke, non-fatal SEE, and death due 
to cardiovascular cause or bleeding. The time to first event will be estimated by a Kaplan-Meier 
estimate and will be compared between rivaroxaban and warfarin using Cox Proportional Hazards 
Model at a significance level of 95%. 
 
Similarly, the other secondary efficacy endpoints (mentioned on Section 2) will be assessed. 
 
If non-inferiority for each secondary efficacy endpoint on the per-protocol population is satisfied, 
then superiority for the respective secondary efficacy endpoint on the ITT population while on 
treatment will be tested. 
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 10.6 Safety Analysis  
 
The Safety Analysis population consists of all randomized subjects who receive at least one dose of 
randomized study drug. The term “on treatment” refers to the period between the first administration 
of study drug and two days after the last administration of study drug. (See section 10.2). This period 
will be the basis for the safety analysis. 
10.6.1   Primary Safety Analysis  
The principal safety end point is a composite of major and nonmajor clinically relevant bleeding 
events. Bleeding endpoints will be presented as rates/100 patient-years of follow-up. The principal 
safety objective of this study is to demonstrate that rivaroxaban is superior to dose-adjusted warfarin 
as assessed by the composite of major and non-major clinically relevant bleeding events. All analyses 
of rates of bleeding will be based on the first event in the safety population during treatment. The Cox 
Proportional Hazards Model with treatment as a covariate will be used and the estimate together with 
the 95% confidence interval will be provided. Kaplan-Meier methodology will be used to estimate 
cumulative event rates over time. Subjects without events during the treatment period will be 
censored. 
10.6.2   Subgroup Safety Analysis  
In order to test for homogeneity across subgroups as far as the primary safety endpoint is concerned, 
the Cox model will also be used to compare patients with major and nonmajor clinically relevant 
bleeding events in terms of demographic and clinical characteristics; for each characteristic, a 
univariate Cox model for the risk of major bleeding will be derived. The following candidate variables 
will be included: Hypertension, Abnormal renal/liver function, history of Stroke, Bleeding history, 
Drugs/alcohol abuse, age ,sex, use of aspirin and prior peptic ulcer disease. 
10.6.3   Secondary Safety Analysis  
The incidence of confirmed major bleeding events, confirmed clinically relevant non-major bleeding 
events, minor bleeding events and all bleeding AEs occurring throughout the treatment period will be 
summarized by treatment group and analyzed separately using the methodology described above. 
 
Furthermore, the number and percentage of subjects with persistent elevation of liver enzymes (ALT, 
AST) and TBL will be summarized by treatment regimen. 
 
Moreover, incidences of treatment-emergent adverse events and serious adverse events will be 
compared between the treatment groups based on non-stratified analysis. Logistic regression models 
will be used, if required, to adjust for confounding factors. 
10.7 Interim Analysis 
 
An interim analysis will be performed, when either 50% of the primary efficacy endpoint events, as 
reported by the Clinical Endpoint Committee (CEC), have occurred, or at a maximum of 18 months 
after the first subject is randomized. The purpose of this interim analysis is to stop the study early if it 
is unlikely to establish non-inferiority for the primary efficacy endpoint, if the study were to run to 
completion. In other words the objective of the interim analysis is to stop the study early due to lack of 
efficacy. The study will NOT be terminated early to declare non-inferiority. 
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11 ADVESE EVENTS  
 
11.1 Definitions 
 
An Adverse Event (AE): is any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product and which does not necessarily have a causal 
relationship with this treatment 
 
Serious Adverse Event: A serious AE (SAE) is any untoward medical occurrence that at any dose:  
 results in death  
 is life-threatening (defined as an event in which the subject was at risk of death at the time of 
the event) 
 requires inpatient hospitalization or causes prolongation of existing hospitalization  
 results in persistent or significant disability/incapacity  
 is a congenital anomaly/birth defect  
 is an important medical event 
 
11.2 Severity of Adverse Event 
 
 Mild (Grade 1) - Awareness of event but easily tolerated  
 Moderate (Grade 2) - Discomfort enough to cause some interference with usual activity  
 Severe (Grade 3) - Inability to carry out usual activity 
 Very Severe (Grade 4) - Life-threatening or disabling AE 
 
11.3 Adverse Event Documentation-Reporting 
 
Subjects must be carefully monitored for adverse events. All adverse events occurring after the subject 
has signed the informed consent form must be fully recorded in the subject’s CRF. Each event should 
be described in detail along with start and stop dates, severity, relationship to investigational product, 
action taken and outcome. 
Serious adverse events must immediately (within 24 hours of the investigator’s awareness) be reported 
and must be followed up until resolution or stabilization. If required, and according to local law and 
regulations, serious adverse events must be reported to the Ethics Committee and Regulatory 
Authorities. 
 
Institutional Repository - Library & Information Centre - University of Thessaly
09/12/2017 13:10:11 EET - 137.108.70.7
 12 REFERENCES 
 
Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial 
fibrillation. N Engl J Med 2009;361:1139-1151 
 
Cyrus Mehta; Ping Gao; Deepak L. Bhatt, et al. Optimizing Trial Design Sequential, Adaptive, and 
Enrichment Strategies, Circulation 2009 ;119:597-605 
 
Food and Drug Administration. Guidance for industry: non-inferiority clinical trials. 2010 
 
Granger B.C., Alexander H.J., McMurray J.V. J. , et al. Apixaban versus Warfarin in Patients with 
Atrial Fibrillation, N Engl J Med 2011; 365:981-992 
 
Holmgren, EB. Establishing equivalence by showing that a specified percentage of the effect of the 
active control over placebo is maintained. J Biopharmaceutical Statistics 1999;9(4):651-659 
 
Hung HMJ, Wang SJ, Tsong Y, Lawrance J, O’Neil RT. Some fundamental issues with non-
inferiority testing in active controlled trials. Statistics in Medicine 2003;22: 213-225 
 
Jackson K., Gersh J.B., Stockbridge N., et al. Antithrombotic drug development for atrial fibrillation: 
Proceedings, Washington, DC, July 25-27, 2005, American Heart Journal 2008, 155(5):829-
840 
 
Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after 
total knee arthroplasty. N Engl J Med 2008;358: 2776-2786 
 
Patel R. M., Mahaffey W. K., Jyotsna Garg, et al. Rivaroxaban versus Warfarin in Nonvalvular Atrial 
Fibrillation, N Engl J Med 2011; 365:883-891 
 
Piaggio G, Elbourne DR, Altman DG, Pocock SJ, Evans SJ. Reporting of noninferiority and 
equivalence randomized trials: an extension of the CONSORT statement. JAMA 
2006;295:1152-1160 
 
ROCKET AF Study Investigators. Rivaroxaban — once daily, oral, direct factor Xa inhibition 
compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial 
Fibrillation: rationale and design of the ROCKET AF study. Am Heart J 2010;159(3): 
340.e1-347.e 
 
Sanchez M, Chen X. Choosing the analysis population in non-inferiority studies: per protocol or 
intent-to-treat. Stat Med 2006;25:1169-1181 
 
Schoenfeld DA. Sample-size formula for the proportional-hazards regression model. Biometrics 
1983;39:499-503 
 
Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic 
medicinal products in non-surgical patients. J Thromb Haemost 2005;3:692-694 
 
Snapinn, SM. Alternatives for Discounting in the Analysis of Non-inferiority Trials. J 
Biopharmaceutical Statistics 2004; 14:263-273 
 
Ware JH, Harrington D, Hunter DJ, D'Agostino RB. Missing data. N Engl J Med 2012;367:1353-1354 
 
Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the 
Framingham Study. Stroke 1991;22: 983-988 
Institutional Repository - Library & Information Centre - University of Thessaly
09/12/2017 13:10:11 EET - 137.108.70.7
